Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2019 Publisher: Aspire Pharma Ltd, Unit 4 Rotherbrook Court, Bedford Road, Petersfield, Hampshire, GU32 3QG, United Kingdom
NORPROLAC 25 micrograms Tablets.
Quinagolide 25 micrograms Tablets.
| Pharmaceutical Form |
|---|
|
Tablet for oral administration. |
Quinagolide, as the hydrochloride, 25 micrograms.
| Active Ingredient | Description | |
|---|---|---|
| Quinagolide |
Quinagolide is a selective dopamine D2-receptor agonist not belonging to the chemical classes of ergot or ergoline compounds. Owing to its dopaminergic action, the drug exerts a strong inhibitory effect on the secretion of the anterior pituitary hormone prolactin, but does not reduce normal levels of other pituitary hormones. |
| List of Excipients |
|---|
|
Iron oxide |
The ‘starter pack’ (NORPROLAC 25/50) consists of 3 tablets of 25 micrograms and 3 tablets of 50 micrograms. These tablets are packed in an aluminium PVC/PVDC blister which is sealed in a moisture proof aluminium bag.
Aspire Pharma Ltd, Unit 4 Rotherbrook Court, Bedford Road, Petersfield, Hampshire, GU32 3QG, United Kingdom
PL 35533/0062
15th December 2004
| Drug | Countries | |
|---|---|---|
| NORPROLAC | Austria, Australia, Canada, Cyprus, Spain, France, Hong Kong, Mexico, Netherlands, Poland, United Kingdom, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
